St. John’s Wort for Vitiligo: A Simple, Low-Cost Way to Partially Ease the Problem
St. John’s wort has long been used in phytomedicine as a natural antidepressant, antispasmodic, and diuretic—and also as a photosensitizer. […]
safety
A Quiet Revolution in Dermatology: How Microcurrents Are Changing the Approach to Treating Vitiligo
Microcurrent Therapy for Vitiligo: A Scientific Review of Innovative Methods Vitiligo is a challenge medicine has been tackling for decades.
Tacrolimus 0.1% for Vitiligo: Efficacy by Zone (Face/Neck vs Trunk vs Acral) — Evidence Overview
Key Takeaways Face/neck respond fastest: perifollicular islands in 4–8 weeks, meaningful F-VASI drops by 8–12 weeks—best as nightly monotherapy or
Tacrolimus 0.1% in Vitiligo: Efficacy by Site (Face/Neck vs Trunk vs Acral) — Evidence Overview
Key Takeaways Face/neck respond best to tacrolimus 0.1%, with earlier perifollicular islands and higher chances of achieving F-VASI50/75 when combined
Pediatric Vitiligo: Therapy, Safety, and Phototherapy Protocols
Key Takeaways First-line on face/neck: calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) as steroid-sparing agents. Backbone for generalized disease: NB-UVB
Tacrolimus 0.1% in Vitiligo: Efficacy by Anatomic Zone (Face/Neck vs Trunk vs Acral)
Key Takeaways Highest efficacy on face/neck with early perifollicular islands; moderate on trunk/limbs; limited on acral sites without phototherapy add-ons.
Excimer 308 nm for Focal Vitiligo (Face/Neck): Protocols, Response Kinetics, and Combinations
Key Takeaways Targeted therapy ideal for focal lesions, active edges, and facial/neck sites; enables high local dose while sparing uninvolved
NB-UVB 311 nm in Nonsegmental Vitiligo: Cohort Outcomes, Protocols, and Site-Specific Response
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo; best outcomes on face/neck, slower on acral sites. Typical schedule 2–3×/week for 24–48
Tofacitinib ± NB-UVB in Vitiligo: Case Series and Open-Label Evidence
Key Takeaways Topical and oral tofacitinib show signals of repigmentation in case series/open studies, with best facial responses. NB-UVB appears